Role of PET to Evaluate Coronary Microvascular Dysfunction in Non-ischemic Cardiomyopathies

Overview

Journal Heart Fail Rev

Date 2017 Jun 4

PMID 28577279

Citations 25

Authors

Paco E Bravo

Marcelo F Di Carli

Sharmila Dorbala

Affiliations

Soon will be listed here.

Abstract

Coronary microvascular dysfunction (CMD) can result from structural and functional abnormalities at the intramural and small coronary vessel level affecting coronary blood flow autoregulation and consequently leading to impaired coronary flow reserve. CMD often co-exists with epicardial coronary artery disease but is also commonly seen in patients with various forms of heart disease, including dilated, hypertrophic, and infiltrative cardiomyopathies. CMD can go unnoticed without any symptoms, or manifest as angina, and/or dyspnea, and contribute to the development of heart failure, and even sudden death especially when co-existing with myocardial fibrosis. However, whether CMD in non-ischemic cardiomyopathy is a cause or an effect of the underlying cardiomyopathic process, or whether it can be potentially modifiable with specific therapies, remains incompletely understood.

Citing Articles

Advances in the diagnosis and management of post-percutaneous coronary intervention coronary microvascular dysfunction: Insights into pathophysiology and metabolic risk interactions.

Tang N, Li K, Li H, Zhang Q, Hao J, Qi C World J Cardiol. 2025; 17(2):103950.

PMID: 40061275 PMC: 11886395. DOI: 10.4330/wjc.v17.i2.103950.

The spectrum and systemic associations of microvascular dysfunction in the heart and other organs.

Emfietzoglou M, Terentes-Printzios D, Kotronias R, Marin F, Montalto C, De Maria G Nat Cardiovasc Res. 2024; 1(4):298-311.

PMID: 39196132 DOI: 10.1038/s44161-022-00045-5.

Myocardial Transit Time Mapping by CMR: A Novel Indicator of Microcirculatory Dysfunction in Cardiac Amyloidosis.

Yang J, Wang Z, Wang H, Zheng P, Deng W, Gao H J Imaging Inform Med. 2024; 37(6):3049-3056.

PMID: 38940890 PMC: 11612126. DOI: 10.1007/s10278-024-01179-7.

The Role of Multimodality Imaging in Cardiomyopathy.

Pan J, Patel A Curr Cardiol Rep. 2024; 26(7):689-703.

PMID: 38753290 PMC: 11236518. DOI: 10.1007/s11886-024-02068-9.

Critical role of the coronary microvasculature in heart disease: From pathologic driving force to "innocent" bystander.

Prakash R, Chakrala T, Feuer D, Valdes C, Pepine C, Keeley E Am Heart J Plus. 2024; 22:100215.

PMID: 38558907 PMC: 10978433. DOI: 10.1016/j.ahjo.2022.100215.

References

Bravo P, Zimmerman S, Luo H, Pozios I, Rajaram M, Pinheiro A . Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2013; 6(2):210-7. PMC: 4124735. DOI: 10.1161/CIRCIMAGING.112.000110. View

Olivotto I, Cecchi F, Gistri R, Lorenzoni R, Chiriatti G, Girolami F . Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2006; 47(5):1043-8. DOI: 10.1016/j.jacc.2005.10.050. View

Schwarz F, Mall G, Zebe H, Blickle J, Derks H, Manthey J . Quantitative morphologic findings of the myocardium in idiopathic dilated cardiomyopathy. Am J Cardiol. 1983; 51(3):501-6. DOI: 10.1016/s0002-9149(83)80088-5. View

Majmudar M, Murthy V, Shah R, Kolli S, Mousavi N, Foster C . Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. Eur Heart J Cardiovasc Imaging. 2015; 16(8):900-9. PMC: 4592320. DOI: 10.1093/ehjci/jev012. View

Varnava A, Elliott P, Sharma S, McKenna W, Davies M . Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000; 84(5):476-82. PMC: 1729476. DOI: 10.1136/heart.84.5.476. View

Range F, Paul M, Schafers K, Acil T, Kies P, Hermann S . Myocardial perfusion in nonischemic dilated cardiomyopathy with and without atrial fibrillation. J Nucl Med. 2009; 50(3):390-6. DOI: 10.2967/jnumed.108.055665. View

Mosseri M, Schaper J, Admon D, Hasin Y, Gotsman M, Sapoznikov D . Coronary capillaries in patients with congestive cardiomyopathy or angina pectoris with patent main coronary arteries. Ultrastructural morphometry of endomyocardial biopsy samples. Circulation. 1991; 84(1):203-10. DOI: 10.1161/01.cir.84.1.203. View

Timmer S, Germans T, Brouwer W, Lubberink M, van der Velden J, Wilde A . Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail. 2011; 13(12):1283-9. DOI: 10.1093/eurjhf/hfr135. View

Kalliokoski R, Kalliokoski K, Sundell J, Engblom E, Penttinen M, Kantola I . Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis. 2005; 28(4):563-73. DOI: 10.1007/s10545-005-0563-2. View

10.

Kovarnik T, Mintz G, Karetova D, Horak J, Bultas J, Skulec R . Intravascular ultrasound assessment of coronary artery involvement in Fabry disease. J Inherit Metab Dis. 2008; 31(6):753-60. DOI: 10.1007/s10545-008-0794-0. View

11.

Krams R, Kofflard M, Duncker D, von Birgelen C, Carlier S, Kliffen M . Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation. 1998; 97(3):230-3. DOI: 10.1161/01.cir.97.3.230. View

12.

Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici P . Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003; 349(11):1027-35. DOI: 10.1056/NEJMoa025050. View

13.

Bravo P, Pinheiro A, Higuchi T, Rischpler C, Merrill J, Santaularia-Tomas M . PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. J Nucl Med. 2012; 53(3):407-14. DOI: 10.2967/jnumed.111.096156. View

14.

Elliott P, Kindler H, Shah J, Sachdev B, Rimoldi O, Thaman R . Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart. 2005; 92(3):357-60. PMC: 1860797. DOI: 10.1136/hrt.2004.054015. View

15.

Knaapen P, Van Campen L, de Cock C, Gotte M, Visser C, Lammertsma A . Effects of cardiac resynchronization therapy on myocardial perfusion reserve. Circulation. 2004; 110(6):646-51. DOI: 10.1161/01.cir.0000138108.68719.c1. View

16.

Drzezga A, BLASINI R, Ziegler S, Bengel F, Picker W, Schwaiger M . Coronary microvascular reactivity to sympathetic stimulation in patients with idiopathic dilated cardiomyopathy. J Nucl Med. 2000; 41(5):837-44. View

17.

Marian A . Challenges in the Diagnosis of Anderson-Fabry Disease: A Deceptively Simple and Yet Complicated Genetic Disease. J Am Coll Cardiol. 2016; 68(10):1051-3. DOI: 10.1016/j.jacc.2016.06.026. View

18.

Sheppard M . The heart in Fabry's disease. Cardiovasc Pathol. 2009; 20(1):8-14. DOI: 10.1016/j.carpath.2009.10.003. View

19.

Maron B, Wolfson J, Epstein S, Roberts W . Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986; 8(3):545-57. DOI: 10.1016/s0735-1097(86)80181-4. View

20.

Sotgia B, Sciagra R, Olivotto I, Casolo G, Rega L, Betti I . Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. J Nucl Med. 2008; 49(7):1090-6. DOI: 10.2967/jnumed.107.050138. View